Zafirlukast-13C,d3
CAT:
804-HY-17492S1-01
Size:
1 mg
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No
Zafirlukast-13C,d3
- UNSPSC Description: Zafirlukast-13C,d3 is the 13C- and deuterium labeled Zafirlukast. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.
- Target Antigen: Isotope-Labeled Compounds; Leukotriene Receptor
- Type: Isotope-Labeled Compounds
- Related Pathways: GPCR/G Protein;Others
- Applications: COVID-19-immunoregulation
- Field of Research: Inflammation/Immunology; Cancer
- Solubility: 10 mM in DMSO
- Smiles: O=C(NC1=CC(C(CC2=CC=C(C(NS(=O)(C3=C(C)C=CC=C3)=O)=O)C=C2O[13C]([2H])([2H])[2H])=CN4C)=C4C=C1)OC5CCCC5
- Molecular Weight: 579.69
- References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223.|[2]Finnerty JP, et al. Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist. Am Rev Respir Dis. 1992 Apr;145(4 Pt 1):746-9.|[3]Gunning WT, et al. Chemoprevention by lipoxygenase and leukotriene pathway inhibitors of vinyl carbamate-induced lung tumors in mice. Cancer Res. 2002 Aug 1;62(15):4199-201.|[4]Lei C, et al. Zafirlukast attenuates advanced glycation end-products (AGEs)-induced degradation of articular extracellular matrix (ECM). Int Immunopharmacol. 2019;68:68-73.
- Shipping Conditions: Room temperature
- Clinical Information: No Development Reported